



# LA AI 2026

## 2<sup>ND</sup> INTERNATIONAL WORKSHOP ON LONG-ACTING ANTI-INFECTIVES

HYBRID WORKSHOP | 20-21 MAY 2026 | PHILADELPHIA, UNITED STATES

30/04/2026

### DAY 1: Wednesday, May 20

00:30	8:30 AM	<b>Welcome Coffee</b>	
00:05	9:00 AM	<b>Official Opening</b>	
<b>Session 1: Long-Acting Platforms</b>			
00:20	9:05 AM	<b>Innovative Modalities for Delivering Long-Acting Antivirals</b>	<b>Andrew Owen</b> , University of Liverpool, United Kingdom
00:15	9:25 AM	<b>GS-1179 and GS-5366: Long-Acting Oral Helicase-Primase Inhibitors for the Treatment of Recurrent Genital Herpes</b>	<b>Alexandre Mercier</b> , Gilead Sciences, Inc., United States
00:15	9:40 AM	<b>Advancing long-acting injectables with BEPO® in situ forming depot technology</b>	<b>Sylvestre Grizot</b> , MedinCell, France
00:15	9:55 AM	<b>NIH DART Center for Ultra-Long-Acting Antiretroviral Release Technologies</b>	<b>Alessandro Gattoni</b> , Center for BioNanoengineering, Houston Methodist Hospital, Houston, Texas, United States
00:10	10:10 AM	<b>Long-Acting Injectable Classification: A System to Guide Product Design, Development, Approval and Market Scaling</b>	<b>Rodney Ho</b> , University of Washington, Washington DC, United States
00:15	10:20 AM	Q & A /Discussion	
00:30	10:35 AM	<b>Coffee Break</b>	
<b>Session 2: Long-Acting Approaches for Prevention</b>			
00:20	11:05 AM	<b>User Preferences and Considerations in Designing Prevention Strategies</b>	<b>José A. Bauermeister</b> , University of Pennsylvania, United States
00:20	11:25 AM	<b>Treatment of HBV as Prevention of Liver Cancer</b>	<b>Chari A. Cohen</b> , Hepatitis B Foundation, Baruch S. Blumberg Institute, United States
00:10	11:45 AM	<b>#1 PrEP-naïve Lenacapavir Initiators More Likely to be Assigned Female Sex at Birth in a Real-World Cohort</b>	<b>Meredith Edwards Clement</b> , Beth Israel Deaconess Medical Center, United States
00:10	11:55 AM	<b>#3 Adherence to Oral versus Long-acting Injectable HIV Preexposure Prophylaxis among Women who Inject Drugs</b>	<b>Douglas Krakower</b> , Beth Israel Deaconess Medical Center, United States
00:10	12:05 PM	<b>#4 Early Patient-Reported Outcomes and Planned Persistence With Lenacapavir for HIV Pre-Exposure Prophylaxis in Routine Clinical Care</b>	<b>Aniruddha Hazra</b> , University of Chicago, United States
00:10	12:15 PM	<b>#2 The Use of PBPK Modelling to Assess the Need for Simultaneous Oral Initiation with Long-Acting Cabotegravir and Rilpivirine in the Setting of Post-exposure Prophylaxis (PEP).</b>	<b>Doaa Ahmed Mohamed</b> , University of Liverpool, United Kingdom
00:20	12:25 PM	Q & A /Discussion	
01:00	12:45 PM	<b>Lunch</b>	
<b>Session 3: Long-Acting Therapeutics Beyond HIV</b>			
00:20	1:45 PM	<b>Update on the Use of Long-acting Monoclonal Antibodies for Malaria Prevention</b>	<b>Kirsten E. Lyke</b> , Center for Vaccine Development and Global Health, United States
00:20	2:05 PM	<b>Long-Acting for Hepatitis C: Treatment and Cure</b>	<b>David Thomas</b> , Johns Hopkins School of Medicine, Baltimore, United States
00:15	2:25 PM	<b>A Shot at Better Adherence: Integrating Long-Acting Injectable Therapies for Tuberculosis</b>	<b>Todd Black</b> , TB Alliance, New York, United States
00:10	2:40 PM	<b>#5 Long-Acting Injectable Treatment for Tuberculosis: Multi-Country Cross-Sectional Study to Examine Preferences, Acceptability, and Trade-Offs</b>	<b>Christopher Vinnard</b> , Gates MRI, United States
00:10	2:50 PM	<b>#6 A Regulatory Strategy for Long-Acting Injectable Regimens for Tuberculosis</b>	<b>Liz Daghlish</b> , Gates MRI, United States
00:15	3:00 PM	Q & A /Discussion	
00:30	3:15 PM	<b>Coffee Break &amp; Poster Viewing</b>	
<b>Session 4: Therapeutic Considerations using LA-ARVS in Key Populations</b>			



00:20	3:45 PM	<b>Behavioral Considerations and Adherence Strategies for People Who Use Drugs</b>	<b>Sunil Solomon,</b> Johns Hopkins University, United States
00:20	4:05 PM	<b>Long-Acting CAB/RPV in Pregnancy: Ready for Prime Time?</b>	<b>William Short,</b> University of Pennsylvania, United States
00:10	4:25 PM	<b>#7 Clinician Attitudes Toward and Utilization of Long-Acting Injectable Cabotegravir/Rilpivirine for Pregnant Persons Living With HIV</b>	<b>Owen M. Parra,</b> University of Pennsylvania, Perelman School of Medicine, United States
00:10	4:35 PM	<b>#8 PREFER-LA: Improved Adherence and Viral Control in Real-World Study of People With HIV in the United States With Adherence Challenges on Oral Antiretroviral Therapy</b>	<b>Elizabeth Moore,</b> ViiV HealthCare, United States
00:10	4:45 PM	<b>#9 Rethinking Eligibility: Long-Acting Cabotegravir/Rilpivirine Achieves Suppression in Viremic Individuals: From the Midway Cohort</b>	<b>Jennifer Kuretski,</b> Midway Specialty Care Center, United States
00:20	4:55 PM	Q & A /Discussion	
	5:15 PM	<b>End of Day 1</b>	
	7:00 PM	<b>Networking Dinner</b>	

## DAY 2: Thursday, May 21

### Session 5: Long-Acting Antiretrovirals - Resistance

00:20	9:00 AM	<b>Development of Resistance to bNABs</b>	<b>Katharine Bar,</b> Perelman School of Medicine, University of Pennsylvania, United States
00:20	9:20 AM	<b>Resistance Globally and Its Impact on the Use of Long-acting Antiretrovirals</b>	<b>Michael Jordan,</b> Tufts University and Tufts Medical Center, Boston, MA, USA Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Lisbon, Portugal
00:10	9:40 AM	<b>#10 How Long-Acting Anti-Infective mAbs Can Catalyze Global mAb Pharmacoequity</b>	<b>Huub Gelderblom,</b> HVTN (HIV Vaccine Trials Network) / Fred Hutchinson Cancer Center, United States
00:10	9:50 AM	<b>#12 ACC085, a novel HIV-1 capsid function inhibitor, exhibits human pharmacokinetics predicted from nonclinical data using a PBPK model, supporting its long-acting potential in humans</b>	<b>Qin Hong,</b> Jiangsuiaidepharmaceutical, China
00:20	10:00 AM	Q & A /Discussion	
00:30	10:20 AM	<b>Coffee Break &amp; Poster Viewing</b>	

### Session 6: Challenges and strategies to managing LA Therapies

#### Chair: Dan Kuritzkes

00:10	10:50 AM	<b>#13 Leveraging Pharmacists and Pharmacy Technicians to Optimize Long-Acting Injectable Antiretroviral Therapy Access, Adherence, and Clinical Outcomes</b>	<b>Katerina A. Christopoulos,</b> University of California San Francisco, United States
00:10	11:00 AM	<b>#14 On-time injection adherence and persistence among people with HIV on long-acting cabotegravir/rilpivirine</b>	<b>Yotam Arens,</b> Weill Cornell Medicine, United States
00:20	11:10 AM	<b>Low-level viremia among people who have already been started on long-acting ART</b>	<b>Ethel Weld,</b> Johns Hopkins University School of Medicine, Baltimore, United States
00:30	11:30 AM	<b>Panel Discussion</b>	Joel Gallant + <Onsite Faculty>

### Session 7: Long-Acting Anti-Infectives: What will the future hold?

00:20	12:00 PM	<b>Delivering monoclonal antibodies using nucleic acids</b>	<b>Pablo Tebas,</b> University of Pennsylvania, United States
00:10	12:20 PM	<b>#15 In-Country Evaluation of Compact Prefilled Autodisable Devices for Delivery of Long-Acting Medicines in Uganda and Zambia</b>	<b>Sarah Sterner,</b> PATH, United States
00:10	12:30 PM	<b>#16 A Novel Islatravir Prodrug Formulated as a Long-Acting Nanosuspension for HIV Treatment</b>	<b>Sijia Tao,</b> Emory University, United States
00:10	12:40 PM	<b>#17 Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184</b>	<b>Hyunmoon Back,</b> GSK, United States
00:10	12:50 PM	<b>#18 Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Twice-Yearly Dosing</b>	<b>Jose R. Castillo-Mancilla,</b> ViiV HealthCare, United States
00:10	1:00 PM	Q & A /Discussion	
00:05	1:10 PM	Closing Remarks	
	1:15 PM	<b>End of the Program</b>	